Advertisement

Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus

      Type 2 diabetes mellitus (T2DM) has evolved as a pandemic of the 21st century, while cardiovascular disease (CVD) affects almost one third of patients and represents the cause of death in more than half cases, with coronary artery disease, heart failure (HF), and stroke being the main contributors.
      • Einarson TR
      • Acs A
      • Ludwig C
      • Panton UH
      Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.
      Hallmark cardiovascular outcome trials published during the last five years have established a novel class of antidiabetics, namely sodium-glucose co-transporter-2 (SGLT-2) inhibitors as a primary treatment option in patients with HF, atherosclerotic cardiovascular disease, or chronic kidney disease, along with the use of metformin (unless not tolerated or contraindicated).
      • Buse JB
      • Wexler DJ
      • Tsapas A
      • Rossing P
      • Mingrone G
      • Mathieu C
      • D'Alessio DA
      • Davies MJ
      2019 update to: management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetes Care. 2020 Jul;43(7):1670].
      Of note, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial demonstrated significant cardiovascular benefit (risk for HF decompensation or cardiovascular death) for patients with HF with reduced ejection fraction, regardless of T2DM status, extending the therapeutic potential of this drug class beyond diabetic subjects.
      • McMurray JJV
      • Solomon SD
      • Inzucchi SE
      • Køber L
      • Kosiborod MN
      • Martinez FA
      • Ponikowski P
      • Sabatine MS
      • Anand IS
      • Bělohlávek J
      • Böhm M
      • Chiang CE
      • Chopra VK
      • de Boer RA
      • Desai AS
      • Diez M
      • Drozdz J
      • Dukát A
      • Ge J
      • Howlett JG
      • Katova T
      • Kitakaze M
      • Ljungman CEA
      • Merkely B
      • Nicolau JC
      • O'Meara E
      • Petrie MC
      • Vinh PN
      • Schou M
      • Tereshchenko S
      • Verma S
      • Held C
      • DeMets DL
      • Docherty KF
      • Jhund PS
      • Bengtsson O
      • Sjöstrand M
      • Langkilde AM
      DAPA-HF Trial Committees and Investigators
      Dapagliflozin in patients with heart failure and reduced ejection fraction.
      Despite the undoubted cardiovascular benefits observed with SGLT-2 inhibitors, the underlying mechanisms of their action remain largely unknown.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Einarson TR
        • Acs A
        • Ludwig C
        • Panton UH
        Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017.
        Cardiovasc Diabetol. 2018; 17: 83
        • Buse JB
        • Wexler DJ
        • Tsapas A
        • Rossing P
        • Mingrone G
        • Mathieu C
        • D'Alessio DA
        • Davies MJ
        2019 update to: management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [published correction appears in Diabetes Care. 2020 Jul;43(7):1670].
        Diabetes Care. 2020; 43: 487-493
        • McMurray JJV
        • Solomon SD
        • Inzucchi SE
        • Køber L
        • Kosiborod MN
        • Martinez FA
        • Ponikowski P
        • Sabatine MS
        • Anand IS
        • Bělohlávek J
        • Böhm M
        • Chiang CE
        • Chopra VK
        • de Boer RA
        • Desai AS
        • Diez M
        • Drozdz J
        • Dukát A
        • Ge J
        • Howlett JG
        • Katova T
        • Kitakaze M
        • Ljungman CEA
        • Merkely B
        • Nicolau JC
        • O'Meara E
        • Petrie MC
        • Vinh PN
        • Schou M
        • Tereshchenko S
        • Verma S
        • Held C
        • DeMets DL
        • Docherty KF
        • Jhund PS
        • Bengtsson O
        • Sjöstrand M
        • Langkilde AM
        • DAPA-HF Trial Committees and Investigators
        Dapagliflozin in patients with heart failure and reduced ejection fraction.
        N Engl J Med. 2019; 381: 1995-2008
        • Desai CS
        • Bartz TM
        • Gottdiener JS
        • Lloyd-Jones DM
        • Gardin JM
        Usefulness of left ventricular mass and geometry for determining 10-year prediction of cardiovascular disease in adults aged >65 years (from the Cardiovascular Health Study).
        Am J Cardiol. 2016; 118: 684-690
        • Bluemke DA
        • Kronmal RA
        • Lima JA
        • Liu K
        • Olson J
        • Burke GL
        • Folsom AR
        The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study.
        J Am Coll Cardiol. 2008; 52: 2148-2155
        • Kawel-Boehm N
        • Kronmal R
        • Eng J
        • Folsom A
        • Burke G
        • Carr JJ
        • Shea S
        • Lima JAC
        • Bluemke DA
        Left ventricular mass at MRI and long-term risk of cardiovascular events: the Multi-Ethnic Study of Atherosclerosis (MESA).
        Radiology. 2019; 293: 107-114
        • Verma S
        • Garg A
        • Yan AT
        • Gupta AK
        • Al-Omran M
        • Sabongui A
        • Teoh H
        • Mazer CD
        • Connelly KA
        Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?.
        Diabetes Care. 2016; 39: e212-e213
        • Deeks JJ
        • Higgins JPT
        • Altman DG
        Chapter 9: Analyzing data and undertaking meta-analyses.
        in: Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011
      1. Review Manager (RevMan) [Computer program] Version [5.3].
        The Nordic Cochrane Centre TCC, Copenhagen2014
        • Higgins JPT
        • Sterne JAC
        • Savović J
        • Page MJ
        • Hróbjartsson A
        • Boutron I
        • Reeves B
        • Eldridge S
        A revised tool for assessing risk of bias in randomized trials.
        Cochrane Database Syst Rev. 2016; 10: 29-31
        • Singh JSS
        • Mordi IR
        • Vickneson K
        • Fathi A
        • Donnan PT
        • Mohan M
        • Choy AMJ
        • Gandy S
        • George J
        • Khan F
        • Pearson ER
        • Houston JG
        • Struthers AD
        • Lang CC
        Dapagliflozin versus placebo on left ventricular remodeling in patients with diabetes and heart failure: the REFORM Trial.
        Diabetes Care. 2020; 43: 1356‐1359
        • Verma S
        • Mazer CD
        • Yan AT
        • Mason T
        • Garg V
        • Teoh H
        • Zuo F
        • Quan A
        • Farkouh ME
        • Fitchett DH
        • Goodman SG
        • Goldenberg RM
        • Al-Omran M
        • Gilbert RE
        • Bhatt DL
        • Leiter LA
        • Jüni P
        • Zinman B
        • Connelly KA
        Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.
        Circulation. 2019; 140: 1693‐1702
        • Brown AJM
        • Gandy S
        • McCrimmon R
        • Houston JG
        • Struthers AD
        • Lang CC
        A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial [published online ahead of print, 2020 Jun 24].
        Eur Heart J. 2020; : ehaa419https://doi.org/10.1093/eurheartj/ehaa419
        • Levelt E
        • Mahmod M
        • Piechnik SK
        • Ariga R
        • Francis JM
        • Rodgers CT
        • Clarke WT
        • Sabharwal N
        • Schneider JE
        • Karamitsos TD
        • Clarke K
        • Rider OJ
        • Neubauer S
        Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes.
        Diabetes. 2016; 65: 44‐52
        • Hsu JC
        • Wang CY
        • Su MM
        • Lin LY
        • Yang WS
        Effect of empagliflozin on cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes mellitus.
        Sci Rep. 2019; 9: 15348